

ARGENICA AWARDED FUNDING UNDER THE AUSTRALIAN GOVERNMENT'S TTRA PROGRAM

Highlights:

- *Argenica has been awarded non-dilutive funding **up to a total of \$1.5M** under the Australian Government's Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator program for Diabetes and Cardiovascular Disease, delivered by MTPConnect.*
- *The funding covers activities to support Argenica's proposed **later stage clinical trial** of ARG-007 in acute ischaemic stroke patients.*
- *The funding will be paid in two tranches, with the first tranche totalling \$1M, and a further \$500,000 provided on successful completion of activities under the first tranche and if the project demonstrates high commercial potential.*

Perth, Australia; 20 June, 2025 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to announce it has been awarded funding through the highly competitive Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator program for Diabetes and Cardiovascular Disease, delivered by [MTPConnect](#).

Under the program, Argenica may receive up to \$1.5M across 2 tranches, with the initial tranche totalling \$1M now secured. These funds will support the Australian-based activities in a global Phase 2b/3 pivotal trial, led from Australia, aiming to demonstrate the efficacy of ARG-007 in reducing global disability following acute ischaemic stroke.

The planned Phase 2b/3 program follows the Company's recently completed Phase 2 clinical trial conducted in Australia, which concluded enrolment in April 2025, exceeding recruitment targets. Data from this trial is anticipated in Q3 2025.

The Company will retain full ownership of all intellectual property and commercialisation rights related to the program. Argenica will now work with MTPConnect to finalise the funding agreements and terms by 30 June 2025.

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has recently completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is now conducting a Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.

For personal use only